# Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

Study · id `cardio:ct-nct04308031` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04308031](<https://clinicaltrials.gov/study/NCT04308031>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04308031

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04308031. Randomized; no masking; primary purpose treatment. Start 2018-08-26 (actual); primary completion 2020-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04308031, source copy `cardio:ctgov-nct04308031-2020-03-13`, retrieved 2026-10-26)
- Started: 2018-08-26 (actual) (ClinicalTrials.gov record NCT04308031, source copy `cardio:ctgov-nct04308031-2020-03-13`, retrieved 2026-10-26)
- Primary completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT04308031, source copy `cardio:ctgov-nct04308031-2020-03-13`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT04308031, source copy `cardio:ctgov-nct04308031-2020-03-13`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT04308031, source copy `cardio:ctgov-nct04308031-2020-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04308031-2020-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
- Condition: Atrial Fibrillation
- Condition: Ivabradine
- Condition: Heart Failure
- Intervention (Drug): Ivabradine 5 mg \[Corlanor\]
- Intervention (Drug): Digoxin 0.25 mg
- Lead sponsor: Chun-Yao Huang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: d311bab402cd5df2815f05478785645af3776fc3d422c789014ae2ba4406170e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
